I am a
Home I AM A Search Login

Papers of the Week

2020 Sep 09

Respir Res


Suppl 1

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology br



Navafenterol (AZD8871) is an inhaled long-acting dual-pharmacology muscarinic antagonist/β-adrenoceptor agonist (MABA) in development for the treatment of obstructive airways diseases. The safety, tolerability, pharmacodynamics, and pharmacokinetics of navafenterol were investigated in patients with mild asthma.